Skip to content

13F-HR filed by Caligan Partners LP

Caligan Partners LP filed this 13F-HR for the quarter ended 2024-09-30, filed 2024-11-14, with 12 holding rows worth $315,472,882.

Accession
0001420506-24-002574
Filed
2024-11-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2024

A holdings report, 12 entries on the cover page, a total value of $315,472,882 stated on the cover page (in dollars after the unit check, H1), rows summing to $315,472,882 with VALUE read as dollars as filed, 13F file number 028-23096. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
LIQUIDIA CORPORATION COM NEW53635D202Stock8,118,592$81,185,920dollars as filed
VERONA PHARMA PLC925050106SPONSORED ADS1,436,878$41,338,980dollars as filed
EXELIXIS INC COM30161Q104Stock1,525,730$39,592,694dollars as filed
EVOLUS INC30052C107COM2,193,488$35,534,506dollars as filed
ANIKA THERAPEUTICS INC035255108COM1,435,130$35,447,711dollars as filed
AGIOS PHARMACEUTICALS INC00847X104COM579,717$25,756,826dollars as filed
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock2,583,585$19,635,246dollars as filed
Y-mAbs Therapeutics Inc984241109Common Stock1,195,253$15,717,577dollars as filed
MINERALYS THERAPEUTICS INC603170101COM981,155$11,881,787dollars as filed
NOVABRIDGE BIOSCIENCES44975P103CMN3,499,330$4,339,169dollars as filed
ENANTA PHARMACEUTICALS INC29251M106COM322,453$3,340,613dollars as filed
OUTLOOK THERAPEUTICS INC69012T305COM318,699$1,701,853dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001420506-24-002574this filing2024-11-14acceptance time not in the bulk data set